The noradrenergic system, centered on the locus coeruleus (LC), is the primary source of norepinephrine (NE) in the central nervous system. This widespread neuromodulatory system regulates attention, arousal, stress response, mood, and autonomic function. The locus coeruleus is one of the earliest brain regions affected in Alzheimer's disease and shows significant degeneration in Parkinson's disease. This pathway page covers norepinephrine synthesis, receptor signaling, and the role of the noradrenergic system in neurodegenerative diseases [1].
| Component | Type | Function | Disease Relevance |
|---|---|---|---|
| TH | Enzyme | Rate-limiting for catecholamine synthesis | LC degeneration marker [2] |
| AADC | Enzyme | DOPA to Dopamine | Essential for NE synthesis [3] |
| DBH | Enzyme | Dopamine to Norepinephrine | LC neuron marker [4] |
| NET | Transporter | NE reuptake | Drug target [5] |
| MAO | Enzyme | NE degradation | Drug target |
| α1-AR | Receptor | Gq, excitatory | Memory, attention [6] |
| α2-AR | Receptor | Gi, inhibitory/autoreceptor | Modulation [7] |
| β-ARs | Receptor | Gs, excitatory | Arousal, metabolism [8] |
Norepinephrine is synthesized through a multi-step enzymatic pathway [3:1]:
The locus coeruleus (LC) is the primary source of central NE, with projections to the cortex, hippocampus, thalamus, cerebellum, and spinal cord.
NE is metabolized primarily by monoamine oxidase (MAO), producing MHPG (3-methoxy-4-hydroxyphenylglycol), which is further metabolized to VMA (vanillylmandelic acid).
The locus coeruleus is a small nucleus in the pons:
The LC shows early and severe degeneration in several neurodegenerative diseases [9][10]:
The LC is among the earliest and most severely affected regions in AD [2:1][11][12]:
Noradrenergic dysfunction contributes to [14][15]:
The LC is severely affected in PD [4:1][9:1]:
Noradrenergic dysfunction contributes to [17][7:1]:
Beta-2 adrenergic receptors on microglia represent an emerging therapeutic target. Activation of β2-AR can modulate neuroinflammation [18] and may influence AD pathology through microglial regulation [8:2].
Various. Sex-dependent locus coeruleus vulnerability in Alzheimer's disease: gut dysbiosis as a driver and probiotic intervention as rescue. Cell Host Microbe. 2025. ↩︎
Various. Early Locus Coeruleus noradrenergic axon loss drives olfactory dysfunction in Alzheimer's disease. Nat Neurosci. 2024. ↩︎ ↩︎
Various. Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease. Pharmacol Rev. 2023. ↩︎ ↩︎
Various. Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer disease and Parkinson disease. Neurology. 2024. ↩︎ ↩︎ ↩︎
Various. Atomoxetine Drug Properties for Repurposing as a Candidate Alzheimer Disease Therapeutic Agent. J Alzheimers Dis. 2024. ↩︎ ↩︎
Various. Deciphering the Role of Adrenergic Receptors in Alzheimer's Disease: Paving the Way for Innovative Therapies. Pharmacol Res. 2025. ↩︎ ↩︎
Various. Noradrenergic alpha(2) Receptor Modulates Cav2.2-Mediated Nociception in Parkinson's Disease Through Spinal Neuro-glial Network. J Neurosci. 2024. ↩︎ ↩︎
Various. Noradrenergic signaling controls Alzheimer disease pathology via activation of microglial beta2 adrenergic receptors. Nat Neurosci. 2025. ↩︎ ↩︎ ↩︎
Various. Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease. Acta Neuropathol. 2025. ↩︎ ↩︎
Various. Pathways underlying selective neuronal vulnerability in Alzheimer's disease: Contrasting the vulnerable locus coeruleus to the resilient substantia nigra. Acta Neuropathol. 2024. ↩︎
Various. Impact of noradrenergic inhibition on neuroinflammation and pathophysiology in mouse models of Alzheimer's disease. Brain. 2024. ↩︎
Various. Locus coeruleus integrity and neuropsychiatric symptoms in a cohort of early- and late-onset Alzheimer's disease. Neurology. 2024. ↩︎
Various. Locus coeruleus signal intensity and emotion regulation in agitation in Alzheimer's disease. Am J Geriatr Psychiatry. 2024. ↩︎
Various. Locus Coeruleus-Norepinephrine System: Spheres of Influence and Contribution to the Development of Neurodegenerative Diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2024. ↩︎
Various. Noradrenaline Regulation of Brain-Body Communication. Nat Rev Neurosci. 2025. ↩︎
Various. Norepinephrine Drives Sleep Fragmentation Activation of Asparagine Endopeptidase, Locus Ceruleus Degeneration, and Hippocampal Amyloid-beta(42) Accumulation. Cell. 2024. ↩︎ ↩︎
Various. EEG Frequency Correlates with alpha(2)-Receptor Density in Parkinson's Disease. Mov Disord. 2024. ↩︎
Various. Neuroinflammation and noradrenergic modulation with β2-adrenoceptors: Emerging therapeutic targets for Parkinson's diseases. Front Neurosci. 2024. ↩︎
Various. Locus coeruleus integrity correlates with plasma soluble Axl levels in Alzheimer's disease patients. Alzheimers Dement. 2025. ↩︎